A REVIEW: THE ROLE OF SNPS IN HBB, BCL11A, HBS1L-MYB, AND MIRNA NETWORKS IN BETA-THALASSEMIA: INSIGHTS FROM IRAQI AND ASIAN POPULATIONS

Haider Qassim Raheem; Haider Turky Mousa AL-Mousawi; Yasir Haider Al-Mawlah; Humam Fadel Al-Sultani; Hussein Fadil I brahim; Shatha Ruaidh Shather; Hawraa Majid Hassan; Sajjad Haider Jasim

doi:10.61796/ijmi.v3i2.436

Authors

Haider Qassim Raheem
[email protected]
University of Babylon, Iraq
Haider Turky Mousa AL-Mousawi Al-Qasim Green University, Iraq
Yasir Haider Al-Mawlah University of Babylon, Iraq
Humam Fadel Al-Sultani Al-Qasim Green University, Iraq
Hussein Fadil I brahim University of Babylon, Iraq
Shatha Ruaidh Shather University of Babylon, Iraq
Hawraa Majid Hassan University of Babylon, Iraq
Sajjad Haider Jasim University of Babylon, Iraq

Vol. 3 No. 2 (2026): International Journal Multidisciplinary (IJMI)

Articles

January 19, 2026

Downloads

VIEW ARTICLE

Abstract
How to Cite
Metrics
References
License

Objective: Beta-thalassemia is a genetically heterogeneous blood disorder marked by impaired hemoglobin synthesis, resulting in chronic anemia, multi-organ complications, and changing clinical severity. This review analyzes the essential functions of single-nucleotide polymorphisms (SNPs) in the HBB, BCLⅠⅠA, and HBSⅠL-MYB genes, as well as miRNA regulatory networks, in influencing beta-thalassemia phenotypes, particularly in Iraqi and Asian populations. Method: Many research investigations conducted across Iraq and Asia have highlighted the elevated prevalence and pathogenic significance of the HBB rs334 mutation, which acts as a primary genetic determinant of the disease in these regions. Additionally, regional studies have shown strong statistical links between BCLⅠⅠA variants (rs1427407, rs11886868) and HBSⅠL-MYB variants (rs4895441, rs9399137) and higher levels of fetal hemoglobin (HbF). Results: This leads to milder phenotypes, less need for transfusions, and better clinical outcomes. These results demonstrate the vital role of genetic modifiers in influencing disease severity. Moreover, the dysregulation of microRNAs—specifically miR-144/451, miR-15a/16-1, and miR-210—has been demonstrated to impact erythropoiesis, hemoglobin switching, and inflammation, thereby further influencing disease progression. According to epidemiological statistics from the World Health Organization and recent studies, the prevalence of beta-thalassemia in Iraq is around 37.1 per 100,000 individuals, with a carrier rate varying from 1.5% to 3% in different Asian areas and peaking at 20% in some ethnic groups. Up to 20% of patients with beta-thalassemia major in Iraq are co-infected with hepatitis C virus owing to their blood transfusion requirements, underscoring the critical need for comprehensive prevention measures. Novelty: The combination of genetic markers and miRNA profiles makes it possible to use personalized diagnostic and treatment methods, especially gene- and miRNA-based therapies that target specific molecular pathways. This review underscores the necessity of tailoring genetic counseling, screening, and management strategies to accommodate unique regional genetic backgrounds and modifier effects, thereby promoting precision medicine and enhancing the quality of care for beta-thalassemia patients in Iraq, Asia, and analogous populations internationally.

Qassim Raheem, H., AL-Mousawi, H. T. M., Al-Mawlah, Y. H., Al-Sultani, H. F., brahim, H. F. I., Shather, S. R., … Jasim, S. H. (2026). A REVIEW: THE ROLE OF SNPS IN HBB, BCL11A, HBS1L-MYB, AND MIRNA NETWORKS IN BETA-THALASSEMIA: INSIGHTS FROM IRAQI AND ASIAN POPULATIONS. International Journal Multidisciplinary (IJMI), 3(2), 203–221. https://doi.org/10.61796/ijmi.v3i2.436

Download Citation

Y. K. Lee et al., “Recent progress in laboratory diagnosis of thalassemia and hemoglobinopathy,” Blood Res., vol. 54, pp. 17–22, 2019, doi: 10.5045/br.2019.54.1.17.

T. Munkongdee et al., “Update in laboratory diagnosis of thalassemia,” Front. Mol. Biosci., vol. 7, p. 74, 2020, doi: 10.3389/fmolb.2020.00074.

S. L. Thein and D. Rees, “Haemoglobin and the inherited disorders of globin synthesis,” in Postgraduate Haematology, 7th ed., A. V. Hoffbrand et al., Eds. Hoboken, NJ: Wiley-Blackwell, 2015, pp. 72–97.

S. G. Musharraf et al., “β-thalassemia patients revealed significant metabolic changes,” Sci. Rep., vol. 7, p. 42249, 2017, doi: 10.1038/srep42249.

J. D. Atmakusuma et al., “Correlation between iron overload and endocrine function in adult β-thalassemia,” Bali Med. J., vol. 10, no. 3, pp. 1238–1244, 2021.

D. T. Kremastinos et al., “β-thalassemia cardiomyopathy,” Circ. Heart Fail., vol. 3, no. 3, pp. 421–428, 2010, doi: 10.1161/CIRCHEARTFAILURE.109.907682.

L. Rujito et al., “Potential use of microRNA technology in thalassemia therapy,” J. Clin. Med. Res., vol. 16, no. 9, pp. 411–422, 2024.

N. Bianchi et al., “Increase of microRNA-210 following mithramycin treatment,” PLoS One, vol. 10, no. 4, e0121567, 2015.

P. Penglong et al., “Expression of microRNA-155 in thalassemic erythropoiesis,” PeerJ, vol. 2024, p. 18054, 2024, doi: 10.7717/peerj.18054.

R. Riyanti and I. D. G. Aryanti, “Effect of anti-miRNA 144 and 150 on α-globin expression,” J. SCRTE, vol. 6, no. 2, 2022.

J. Zhang, J. Yan, and F. Zeng, “Recent progress on genetic diagnosis and therapy for β-thalassemia,” Hum. Gene Ther., vol. 29, no. 2, pp. 197–203, 2018.

E. M. Hamed et al., “Recent progress in gene therapy for β-thalassemia,” Curr. Drug Targets, vol. 20, no. 16, pp. 1603–1623, 2019.

R. Origa, “β-thalassemia,” Genet. Med., vol. 19, no. 6, pp. 609–619, 2017.

A. Kattamis et al., “Changing epidemiology of β-thalassemia,” Eur. J. Haematol., vol. 105, no. 6, pp. 692–703, 2020.

R. Malakar et al., “A review on β-thalassemia,” World J. Pharm. Res., vol. 5, no. 6, pp. 432–445, 2016.

M. Bejaoui and N. Guirat, “β-thalassemia major in developing countries,” Mediterr. J. Hematol. Infect. Dis., vol. 5, no. 1, e2013002, 2013.

X. Xu and X. Wu, “Epidemiology and treatment of β-thalassemia major in China,” Pediatr. Investig., vol. 4, no. 1, pp. 43–47, 2020.

H. A. Wadaha et al., “Coagulation changes in β-thalassemia,” Med. J. Babylon, vol. 19, no. 2, pp. 157–161, 2022.

Anonymous, “Gene structure: Family of genes,” Oct. 17, 2025.

A. Cao and R. Galanello, “Beta-thalassemia,” Genet. Med., vol. 12, no. 2, pp. 61–76, 2010.

S. Ali et al., “Current status of beta-thalassemia,” Mol. Genet. Genomic Med., vol. 9, no. 12, e1788, 2021.

T. Aksu and S. Unal, “Thalassemia,” Trends Pediatr., vol. 2, no. 1, pp. 1–7, 2021.

C. Asadov et al., “β-thalassemia intermedia,” Int. J. Hematol., vol. 108, no. 1, pp. 5–21, 2018.

P. Ropero et al., “β-thalassemia intermedia in Spain,” Front. Med., vol. 9, p. 866396, 2022.

V. Parthasarathy, “Search for beta-thalassemia trait in India,” Turk. J. Haematol., vol. 29, no. 4, p. 427, 2012.

N. Tesio and D. E. Bauer, “Molecular basis and genetic modifiers,” Hematol. Oncol. Clin. North Am., vol. 37, no. 2, pp. 273–299, 2023.

S. L. Thein, “Molecular basis of β-thalassemia,” Blood Cells Mol. Dis., vol. 70, pp. 54–65, 2018.

S. K. Topfer et al., “Disrupting the adult globin promoter,” Blood, vol. 139, no. 14, pp. 2107–2118, 2022.

S. L. Thein, “Molecular basis of β-thalassemia,” Cold Spring Harb. Perspect. Med., vol. 3, no. 5, a011700, 2013.

D. J. Weatherall, “Phenotype-genotype relationships,” Nat. Rev. Genet., vol. 2, no. 4, pp. 245–255, 2001.

S. Fucharoen and D. J. Weatherall, “Hemoglobin E thalassemias,” Cold Spring Harb. Perspect. Med., vol. 2, no. 8, a011734, 2012.

S. L. Thein and W. G. Wood, “Molecular basis of β-thalassemia,” in Disorders of Hemoglobin, Cambridge Univ. Press, 2009, pp. 323–356.

N. N. Jawad and M. N. Al-Terehi, “Variation of DNA repair genes in β-thalassemia,” Med. J. Babylon, vol. 21, no. 4, pp. 844–847, 2024.

G. D. Efremov, “Hemoglobins Lepore,” Hemoglobin, vol. 2, no. 3, pp. 197–233, 1978.

L. Perseu et al., “KLF1 gene mutations,” Blood, vol. 118, no. 16, pp. 4454–4458, 2011.

R. Galanello et al., “Somatic deletion of β-globin gene,” Br. J. Haematol., vol. 127, no. 5, pp. 604–606, 2004.

J. G. Chang et al., “Evolution from β-thalassemia minor,” Haematologica, vol. 93, no. 6, pp. 913–916, 2008.

A. M. Brunner and D. P. Steensma, “Myelodysplastic syndrome with acquired β-thalassemia,” Am. J. Hematol., vol. 91, no. 8, pp. E325–E327, 2016.

N. T. Al-Musawe and M. K. Al-Malkey, “Parvovirus B19 in β-thalassemia,” Al-Rafidain J. Med. Sci., vol. 8, no. 2, pp. 41–46, 2025.

N. M. Rashid and A. A. Sultan, “HBB polymorphisms in Iraq,” Iraq Med. J., vol. 8, no. 2, 2024.

H. Kocak Eker and O. Balasar, “HBB variants in Turkey,” Mol. Syndromol., vol. 15, no. 5, pp. 362–370, 2024.

A. H. Odah Al-Musawi et al., “HBB mutations in Southern Iraq,” Biomedicine, 2022.

S. Dadheech et al., “BCL11A variant and disease severity,” Indian J. Med. Res., vol. 143, no. 4, pp. 449–454, 2016.

A. A. Bhanushali et al., “BCL11A variant and HbF,” Blood Cells Mol. Dis., vol. 54, no. 1, pp. 4–8, 2015.

S. N. Mtatiro et al., “GWAS of fetal hemoglobin,” PLoS One, vol. 9, no. 11, e111464, 2014.

N. Al-Allawi et al., “HbF polymorphisms in Iraqi Kurds,” Int. J. Lab. Hematol., vol. 41, no. 1, pp. 87–93, 2019.

M. Uda et al., “BCL11A associated with HbF,” Proc. Natl. Acad. Sci. USA, vol. 105, no. 5, pp. 1620–1625, 2008.

N. Al-Allawi et al., “Genetic epidemiology of hemoglobinopathies,” J. Community Genet., vol. 12, no. 1, pp. 5–14, 2021.

S. L. Thein et al., “HBS1L-MYB variants,” Proc. Natl. Acad. Sci. USA, vol. 104, no. 27, pp. 11346–11351, 2007.

G. L. Cardoso et al., “DNA polymorphisms and HbF,” Blood Cells Mol. Dis., vol. 53, no. 4, pp. 176–179, 2014.

W. Prasing et al., “Genotyping of BCL11A and HBS1L-MYB,” Walailak J. Sci. Technol., vol. 15, no. 9, pp. 627–636, 2018.

T. A. Omar et al., “HBS1L-MYB polymorphisms,” Open J. Blood Dis., vol. 10, no. 4, pp. 89–100, 2020.

Z. Q. Mousa and M. A. Dragh, “BCL11A polymorphism,” J. Med. Chem. Sci., vol. 6, no. 4, pp. 834–845, 2023.

N. A. Al-Allawi et al., “Genetic modifiers in β-thalassemia intermedia,” Genet. Test. Mol. Biomarkers, vol. 19, no. 5, pp. 242–247, 2015.

N. Al-Allawi et al., “Genetic scoring system in Iraq,” Hemoglobin, vol. 48, no. 2, pp. 94–100, 2024.

T. Munkongdee et al., “Predictive SNPs for β0-thalassemia/HbE,” Sci. Rep., vol. 11, p. 10352, 2021.

A. K. J. Al-Hameedawi and A. A. A. Al-Shawi, “Novel β-thalassemia mutations,” Mol. Biol. Rep., vol. 50, no. 4, pp. 3053–3062, 2023.

S. D. Jalal et al., “β-thalassemia mutations in Kurds,” Hemoglobin, vol. 34, no. 5, pp. 469–476, 2010.

Y. Ye et al., “Haplotype-resolved genotyping of β-thalassemia,” Adv. Sci., vol. 12, no. 9, e2410992, 2025.

A. Taher et al., Guidelines for the Management of NTDT. Nicosia, Cyprus: Thalassaemia Int. Federation, 2013.

T. Kim and C. M. Croce, “MicroRNA in clinical trials,” Exp. Mol. Med., vol. 55, no. 5, pp. 1234–1250, 2023.

V. Singh et al., “MicroRNA significance in cancer,” Biomedicines, vol. 12, no. 2, p. 230, 2024.

M. Esteller, “Non-coding RNAs in human disease,” Nat. Rev. Genet., vol. 12, no. 12, pp. 861–874, 2011.

F. Wang et al., “MicroRNAs in β-thalassemia,” Am. J. Med. Sci., vol. 362, no. 1, pp. 5–12, 2021.

L. Rujito et al., “Roles of microRNAs in thalassemia,” J. Res. Clin. Med., vol. 13, p. 34673, 2025.

S. M. Nassiri et al., “MicroRNAs in hematopoiesis,” Stem Cell Res. Ther., vol. 14, no. 1, p. 282, 2023.

M. D. Diamantidis et al., “Genetic modifiers of hemoglobin expression,” Int. J. Mol. Sci., vol. 25, no. 22, p. 11886, 2024.

L. Rujito et al., “MicroRNA technology in thalassemia,” J. Clin. Med. Res., vol. 16, no. 9, pp. 411–422, 2024.

N. H. Eltaweel et al., “Epigenetic effects in β-thalassemia,” J. Genet. Eng. Biotechnol., vol. 19, no. 1, p. 51, 2021.

B. Li et al., “MIR-144-mediated NRF2 silencing,” Exp. Hematol., vol. 70, pp. 85–96.e5, 2019.

K. Boonpeng et al., “Serum microRNAs in G6PD deficiency,” Sci. Rep., vol. 14, p. 16029, 2024.

M. Gabbianelli et al., “Human Hb switching mechanism,” Haematologica, vol. 95, no. 8, 2010.

B. Li et al., “MIR-144-mediated NRF2 silencing,” Exp. Hematol., vol. 70, pp. 85–96.e5, 2019.

N. H. Eltaweel et al., “Epigenetic effects in β-thalassemia,” J. Genet. Eng. Biotechnol., vol. 19, no. 1, p. 51, 2021.

L. Rujito et al., “Circulating microRNA profiling,” ExRNA, vol. 6, no. 3, p. 0011, 2024.

J. Keith et al., “Loss of miR-144/451 alleviates β-thalassemia,” Blood, vol. 142, no. 10, pp. 918–932, 2023, doi: 10.1182/blood.2022017265.

International Journal Multidisciplinary (IJMI)

A REVIEW: THE ROLE OF SNPS IN HBB, BCL11A, HBS1L-MYB, AND MIRNA NETWORKS IN BETA-THALASSEMIA: INSIGHTS FROM IRAQI AND ASIAN POPULATIONS

Authors

Downloads

menubaru

templatebaru

index

Citedne Scopus

Collaboration Institution

Publisher Association

Total Author Journal (302 Authors)

Tools

Keywords

Address

Contact Info: